Amphastar Pharmaceuticals Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $10.8. Which is the better fit depends on your goals.
| AMPH | MSTZ | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $30.81 | $27.92 |
52-Week Low | $16.87 | $3.88 |
Enterprise Value | $1.27B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
MSTZ's stock is currently trading at $10.3, down 6.19% over the past 24 hours, reflecting significant bearish pressure. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and key support levels identified near $9 and $8. The absence of reported financial ratios such as P/E and P/S limits fundamental clarity, while recent news highlights ETF performance unrelated to the company's core business, indicating a lack of direct catalysts.
The outlook for MSTZ appears cautious due to weak technical momentum and limited fundamental visibility. Investment opportunities are constrained by the bearish signal and absence of recent financial data, posing risks from market volatility and potential competitive pressures. Investors should seek updated earnings reports for a clearer assessment of the company's financial health and growth prospects.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →